



# **119th MAINE LEGISLATURE**

### **SECOND REGULAR SESSION-2000**

Legislative Document

No. 2523

S.P. 980

In Senate, February 8, 2000

An Act to Establish Fair Pricing for Prescription Drugs.

Approved for introduction by a majority of the Legislative Council pursuant to Joint Rule 203.

Reference to the Committee on Health and Human Services suggested and ordered printed.

JOY J. O'BRIEN Secretary of the Senate

Presented by Senator PINGREE of Knox. Cosponsored by Representative QUINT of Portland and Senators: President LAWRENCE of York, PARADIS of Aroostook, RAND of Cumberland, RUHLIN of Penobscot, Representatives: DUGAY of Cherryfield, GAGNON of Waterville.

Be it enacted by the People of the State of Maine as follows: 2 Sec. 1. 5 MRSA §12004-E, sub-§4 is enacted to read: 4 22 MRSA \$2682 4. Fair Drug Expenses; 6 Pricing Board Legislative per diem for 8 Legislators: \$35 per day for nonstate 10 employees 12 Sec. 2. 10 MRSA §1105, 2nd ¶ is amended to read: 14 The term "necessities of life" shall-include includes food 16 for human consumption, food for domestic animals, prescription drugs, wearing apparel, shoes, building materials, gas and 18 electricity for light, heat and power, ice, fuel of all kinds, fertilizer and fertilizer ingredients, together with tools, utensils, implements, machinery and equipment required for the 20 actual production or manufacture of the same. 22 Sec. 3. 22 MRSA c. 603 is enacted to read: 24 CHAPTER 603 26 MAINE PRESCRIPTION DRUG FAIR PRICING ACT 28 §2681. Short title 30 This chapter may be known and cited as the "Maine 32 Prescription Drug Fair Pricing Act." 34 §2682. Fair Drug Pricing Board 36 The Fair Drug Pricing Board, referred to in this chapter as the "board," is established. 38 1. Membership. The board consists of the following 11 40 members: 42 A. One Senator, appointed by the President of the Senate; 44 B. One Representative, appointed by the Speaker of the House of Representatives; 46 C. Three members of the public, appointed jointly by the President of the Senate and the Speaker of the House of 48 Representatives, one each representing the interests of the 50 following:

| 2  | (1) Senior citizens;  |
|----|---|
| 4  | (2) Disabled citizens; and  |
| б  | (3) Low-income citizens.  |
| 8  | Members appointed pursuant to this paragraph must be residents of this State and be at least 21 years of age;   |
| 10 |   |
| 12 | D. Two members of the medical community, appointed jointly<br>by the President of the Senate and the Speaker of the House<br>of Representatives, representing the interests of senior |
| 14 | <u>cițizens;</u>  |
| 16 | E. Two pharmacists, appointed by the Governor. The pharmacists must meet the following gualifications in order  |
| 18 | <u>to be appointed to and remain on the board. Neither</u><br>pharmacist may be a member of the Maine Board of Pharmacy.  |
| 20 | Each pharmacist must:   |
| 22 | (1) Be licensed to practice pharmacy in this State and<br>in good standing to do so;  |
| 24 | (2) Be engaged in the practice of pharmacy in this  |
| 26 | <u>State:</u>   |
| 28 | (3) Have at least 5 years of experience in this State<br>as a licensed pharmacist; and  |
| 30 | (4) Be a resident of this State; and  |
| 32 |   |
| 34 | F. The Director of the Bureau of Health within the<br>department and the Commissioner of Professional and<br>Financial Regulation, both who serve as ex officio,                      |
| 36 | nonvoting members.  |
| 38 | <b>2. Terms.</b> Members of the board serve for terms of 3 years and may be reappointed.  |
| 40 |   |
| 42 | 3. Meetings. The board shall meet at least once per month.  |
| 44 | 4. Director: staffing. The Director of the Bureau of<br>Health within the department shall appoint a director who shall   |
| 46 | perform the duties delegated by the board, including the<br>administration of other staff to the board. The department shall  |
| 48 | provide appropriate levels of staffing to assist the board.   |
| 50 | <b>5. Cooperation.</b> In performing its duties, the board shall cooperate and work with the department, the Maine Board of   |

Pharmacy and the Department of Professional and Financial 2 Regulation.

#### 4 §2683. Prescription drug pricing

6 The board shall adopt rules establishing the maximum price for prescription drugs pursuant to this section. Maximum prices 8 established by the board are provisionally adopted pending approval by the Legislature. 10 1. Manufacturers. The maximum price for a prescription drug sold in the State by a manufacturer must be the lower of the 12 price listed in the federal supply schedule for pharmaceuticals 14 and drugs maintained by the United States Department of Veterans Affairs or the price listed in the drug formulary maintained by 16 the Province of Quebec. 18 2. Wholesalers. The maximum price for a prescription drug sold in the State by a wholesaler is the maximum manufacturer 20 price as determined by subsection 1 plus any usual and customary wholesale markup. 22 3. Retailers. The maximum price for a prescription drug 24 sold in the State by a retailer is the maximum wholesale price as determined by subsection 2 plus any usual and customary retail 26 markup. 28 §2684. Prescription drug survey 30 The board, to assist in the development of maximum drug prices pursuant to section 2683, shall conduct a semiannual 32 survey of prescription drugs. 34 1. Survey information. The survey must include the following information: 36 A. Current manufacturer, wholesale and retail maximum 38 prices of prescription drugs in Maine, as set by the board; 40 B. Manufacturer, wholesale and retail maximum prices for prescription drugs for the previous 5 years at 6-month 42 intervals; 44 C. The federal supply schedule for pharmaceuticals and drugs maintained by the United States Department of Veterans 4б Affairs; 48 D. The drug formulary maintained by the Province of Quebec; 50 E. Current data regarding the elderly low-cost drug program

| conducted by the department pursuant to sections 254 and   |  |
|--|--|
|  |  |
| <u>254-B, respectively; and</u>  |  |
|  |  |
| F. Any other information concerning prescription drug  |  |
| prices in the State that the board considers appropriate.  |  |
| 2. Reports. Semiannually, the board shall provide copies   |  |
| of the results of the survey performed pursuant to subsection 1  |  |
| to the Legislature, the department, the Maine Board of Pharmacy  |  |
| and the Department of Professional and Financial Regulation.   |  |
|  |  |
| 3. Internet site. The board shall maintain a publicly  |  |
| accessible site on the Internet containing the results of the  |  |
| survey conducted pursuant to subsection 1.   |  |
|  |  |
| §2685. Appeals   |  |
|  |  |
| A manufacturer of prescription drugs may appeal the maximum  |  |
| price of a prescription drug to the board.   |  |
|  |  |
| 1. Factors in appeal. Factors to be considered by the  |  |
| board in an appeal include the cost of production, the profit  |  |
| through sale and the price charged in other markets for the  |  |
| prescription drug.   |  |
|  |  |
| 2. Appeals to Superior Court. Rulings on appeals by the  |  |
| board may be appealed to the Superior Court in Kennebec County.  |  |
|  |  |
| 3. Disclosure. If a manufacturer of prescription drugs   |  |
|  |  |
| appeals a price set by the board, the manufacturer shall fully   |  |
|  |  |
| appeals a price set by the board, the manufacturer shall fully<br>disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the<br>manufacturer from having to disclose such information.  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the<br>manufacturer from having to disclose such information.<br>4. Effect of appeal. The filing of an appeal may not delay  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the<br>manufacturer from having to disclose such information.  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the<br>manufacturer from having to disclose such information.<br>4. Effect of appeal. The filing of an appeal may not delay<br>the implementation of the maximum price imposed by the board.   |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the<br>manufacturer from having to disclose such information.<br>4. Effect of appeal. The filing of an appeal may not delay  |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the<br>manufacturer from having to disclose such information.<br>4. Effect of appeal. The filing of an appeal may not delay<br>the implementation of the maximum price imposed by the board.<br>§2686. Violations; enforcement   |  |
| <ul> <li>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information.</li> <li>4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board.</li> <li>§2686. Violations: enforcement</li> <li>1. Investigation. The Attorney General shall investigate</li> </ul>   |  |
| disclose to the board information regarding the production costs<br>of the drug and any other information pertinent to the appeal<br>requested by the board, notwithstanding any law protecting the<br>manufacturer from having to disclose such information.<br>4. Effect of appeal. The filing of an appeal may not delay<br>the implementation of the maximum price imposed by the board.<br>§2686. Violations: enforcement<br>1. Investigation. The Attorney General shall investigate<br>any violation by a manufacturer or wholesaler of prescription  |  |
| <ul> <li>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information.</li> <li>4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board.</li> <li>§2686. Violations: enforcement</li> <li>1. Investigation. The Attorney General shall investigate</li> </ul>   |  |
| <ul> <li>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information.</li> <li>4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board.</li> <li>§2686. Violations: enforcement</li> <li>1. Investigation. The Attorney General shall investigate any violation by a manufacturer or wholesaler of prescription drugs sold in this State of any of the following:</li> </ul>   |  |
| <ul> <li>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information.</li> <li>4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board.</li> <li>§2686. Violations: enforcement</li> <li>1. Investigation. The Attorney General shall investigate any violation by a manufacturer or wholesaler of prescription drugs sold in this State of any of the following:</li> <li>A. This chapter, Title 10, section 1105 or Title 32,</li> </ul>                 |  |
| <ul> <li>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information.</li> <li>4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board.</li> <li>§2686. Violations: enforcement</li> <li>1. Investigation. The Attorney General shall investigate any violation by a manufacturer or wholesaler of prescription drugs sold in this State of any of the following:</li> </ul>   |  |
| <pre>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information. 4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board. \$2686. Violations: enforcement 1. Investigation. The Attorney General shall investigate any violation by a manufacturer or wholesaler of prescription drugs sold in this State of any of the following: A. This chapter, Title 10, section 1105 or Title 32, chapter 117;</pre>  |  |
| <pre>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information. 4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board. \$2686. Violations: enforcement 1. Investigation. The Attorney General shall investigate any violation by a manufacturer or wholesaler of prescription drugs sold in this State of any of the following: A. This chapter, Title 10, section 1105 or Title 32, chapter 117; B. Any other state or local law that prohibits</pre> |  |
| <pre>disclose to the board information regarding the production costs of the drug and any other information pertinent to the appeal requested by the board, notwithstanding any law protecting the manufacturer from having to disclose such information. 4. Effect of appeal. The filing of an appeal may not delay the implementation of the maximum price imposed by the board. \$2686. Violations: enforcement 1. Investigation. The Attorney General shall investigate any violation by a manufacturer or wholesaler of prescription drugs sold in this State of any of the following: A. This chapter, Title 10, section 1105 or Title 32, chapter 117;</pre>  |  |

- <u>C. Any state or local law that prohibits the return of part</u>
   <u>of the cost of a drug pursuant to a confidential agreement</u>
   <u>or coercion; or</u>
- D. Any state or local law that prohibits a drug manufacturer or wholesaler from interfering with health care
   providers or retail pharmacies or the patients of health care providers or retail pharmacies.
- 2. Enforcement. If the Attorney General determines that a
   violation of subsection 1 or of any similar federal law has occurred, in addition to any other penalties, the Attorney
   General may recommend to the Maine Board of Pharmacy that the manufacturer's certificate of registration issued pursuant to
   Title 32, chapter 117, subchapter V or VI be revoked or suspended. The Maine Board of Pharmacy may not revoke or suspend
   a manufacturer's certificate of registration if that action would cause the supply of prescription drugs to be restricted, as
   determined by the Fair Drug Pricing Board.
- 3. Petition. The Attorney General also may initiate an investigation upon the written request of at least 50 residents
   of this State alleging excessive manufacturer, wholesale or retail prescription drug prices.
- 26

28

10

#### §2687. Agreements with other entities

- The board may enter into agreements with other states in the 30 Northeast and Canadian provinces for the purpose of maintaining fair and uniform prescription drug prices and ensuring maximum 32 access to affordable prescription drugs.
- 34 §2688. Fund established

36 The Maine Prescription Drug Fair Pricing Fund, referred to in this section as the "fund," is established. An amount equal 38 to any savings that are realized as a result of the implementation of this Act due to a decrease in the costs of the 40 prescription drug insurance plan provided to state employees and retirees, as recommended by the State Employee Health Commission 42 pursuant to Title 5, chapter 13, subchapter II, must be placed in the fund and used to increase the funding levels of the elderly 44 prescription drug program established in section 3174-G. subsection 1-A. Any unexpended amounts in the fund do not lapse 46 but must be carried forward to be used for the same purpose.

#### 48 §2689. Emergency measures

50 The board shall draft a plan that includes emergency measures to be implemented in the event that the board determines that there is a severe limitation or shortage of or loss of
access to prescription drugs in the State that is threatening or
endangering the health or welfare of the public. If the board
determines that such an event is occurring, the board shall
provide the Governor with the plan and petition the Governor to
implement the emergency measures.

#### 8 §2690. Rulemaking

16

34

10 The board shall adopt rules to carry out the purposes of this chapter. Rules adopted pursuant to this chapter are major 12 substantive rules pursuant to Title 5, chapter 375, subchapter II-A. The board shall submit rules to the joint standing 14 committee of the Legislature having jurisdiction over health and human services matters.

Sec. 4. 32 MRSA §13792, as enacted by PL 1987, c. 710, §5, is amended to read:

#### 20 §13792. Sale by certain methods prohibited

It shall-be is unlawful for any person to sell, distribute, vend or otherwise dispose of any drug, medicine or pharmaceutical or medical preparation by means of the Internet or any public exhibition, entertainment, performance, carnival or by vending machines.

28 Sec. 5. Findings; purpose.

30 **1. Findings.** The Legislature makes the following findings.

32 A. The cost of many prescription drugs in this State is excessive and in many cases prohibitive.

B. As a consequence of the excessive cost of prescription
 drugs, far too many Maine citizens are forced to choose
 between purchasing food, heating their homes or purchasing
 their prescription drugs.

- C. As a consequence of the excessive cost of prescription drugs, many Maine citizens are forced into the life-threatening practice of omitting or reducing doses of their prescription medications due to the inability to afford those medications.
- D. Senior citizens and low-income citizens, the persons who can least afford the excessive costs due to inadequate or nonexistent insurance, are the persons who are most often required to make these harsh choices.

2. Purpose. The purposes of this Act are to protect the public health and safety and promote the public interest by
 4 establishing prices for prescription drugs that more adequately reflect the actual costs of those drugs.

Sec. 6. Appointments to Fair Drug Pricing Board; meeting. All appointments to the Fair Drug Pricing Board, as established in the Maine Revised Statutes, Title 22, section 2682, must be made no later than August 15, 2000. The director of the board shall call the first meeting of the board no later than September 1, 2000.

Sec. 7. Initial rules. The Fair Drug Pricing Board shall submit all rules adopted pursuant to the Maine Revised Statutes, Title
 22, chapter 603, including the schedule of prices for prescription drugs, to the joint standing committee of the
 Legislature having jurisdiction over health and human services matters by January 1, 2001. All rules are provisionally adopted, effective May 1, 2001, pending action by the Legislature.

Sec. 8. Appropriation. The following funds are appropriated from the General Fund to carry out the purposes of this Act.

2000-01

\$500,000

\$500,000

26

22

24

6

ATTORNEY GENERAL, 28 DEPARTMENT OF THE

#### **30** Administration - Attorney General

32 All Other

34

|    | Provides a one-time           |
|----|-------------------------------|
| 36 | appropriation for increased   |
|    | staffing and other costs      |
| 38 | related to enforcement of the |
|    | Maine Prescription Drug Fair  |
| 40 | Pricing Act, as established   |
|    | in the Maine Revised          |
| 42 | Statutes, Title 22, chapter   |
|    | 603.                          |
| 44 |                               |

## 46 DEPARTMENT OF THE ATTORNEY GENERAL

48 HUMAN SERVICES, DEPARTMENT OF

| 2  | Fair Drug Pricing Board   |                   |
|----|---|-------------------|
| 4  | Positions - Legislative Count<br>Personal Services  | (1.000)           |
| 6  | All Other   | \$37,500<br>7,500 |
| 8  | TOTAL   | \$45,000          |
| 10 | Provides for the appropriation of funds to  |                   |
| 12 | establish the position of<br>Director of the Fair Drug  |                   |
| 14 | Pricing Board and related<br>staffing pursuant to the   |                   |
| 16 | Maine Revised Statutes, Title<br>22, section 2682, subsection   |                   |
| 18 | 4.  |                   |
| 20 | Fair Drug Pricing Board   |                   |
| 22 | All Other   | \$5,000           |
| 24 | Provides funds to allow the<br>Fair Drug Pricing Board to   |                   |
| 26 | perform a survey of<br>prescription drug prices and   |                   |
| 28 | publish the results of that<br>survey pursuant to the Maine   |                   |
| 30 | Revised Statutes, Title 22,<br>section 2684.  |                   |
| 32 | DEPARTMENT OF HUMAN SERVICES  |                   |
| 34 | TOTAL   | \$50,000          |
| 36 | TOTAL APPROPRIATIONS  | \$550,000         |
| 38 |   | ψ930,000          |
| 40 | SUMMARY   |                   |
| 42 | In order to protect the public health and safety establishment of prescription drug prices that more                              |                   |
| 44 | reflect the actual costs of those prescription drugs, this bill<br>establishes the Maine Prescription Drug Fair Pricing Act. This |                   |
| 46 | bill accomplishes that purpose by doing the following.  | ACC. 1110         |
| 48 | <ol> <li>It establishes the Fair Drug Pricing Board.<br/>with the approval of the Legislature, sets the maximum</li> </ol>        |                   |
| 50 |   | he board is       |

.

required to work with the Department of Human Services, the Department of Professional and Financial Regulation and the Maine 2 Board of Pharmacy and to report regularly to those entities and the Legislature. The board may enter into agreements with other 4 States or Canadian provinces to ensure uniform prices for prescription drugs. The board is also required to maintain an 6 Internet site to give the public access to the price schedule established by the board. 8

The Attorney General is given specific enforcement power 10 2. of the Act. If the Attorney General finds that a violation of 12 certain laws has occurred, the Attorney General may recommend the suspension or revocation of a manufacturer's certificate of registration. If 50 or more Maine citizens petition the Attorney 14 General alleging excessive prescription drug prices, the Attorney General is required to investigate. 16

- 18 The sale of prescription drugs over the Internet is 3. prohibited.
- 20 4. The current prohibition against profiteering in
- 22 necessities is expanded to include prescription drugs.